Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.
Saved in:
| Title: | Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective. |
|---|---|
| Authors: | Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gadi VK; Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL, USA., Pathak P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Delea T; Avalere Health, Boston, MA, USA., Stellato D; Avalere Health, Boston, MA, USA. |
| Source: | Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 2125-2134. Date of Electronic Publication: 2025 Dec 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
